Search

Displaying results 2341 - 2350 of 5392 in total
  1. Drug

    Amivantamab

    go.drugbank.com/drugs/DB16695
    ApprovedInvestigational

    [A235103,A235123] Patients with NSCLC with exon 20 insertion mutations in EGFR do not respond to tyrosine kinase inhibitors, and were generally treated with platinum-based therapy.

  2. Drug

    Clobutinol

    go.drugbank.com/drugs/DB09004
    ApprovedWithdrawn

    Clobutinol is a cough suppressant that is withdrawn from the US and EU markets. Clobutinol may prolong the QT interval. In 2007, Clobutinol was determined to cause cardiac arrhythmia in some patients.

  3. Drug

    Guanoxan

    go.drugbank.com/drugs/DB13211
    Approved

    Guanoxan was approved in the UK but was withdrawn from the market due to hepatotoxicity.

  4. Drug

    Cipepofol

    go.drugbank.com/drugs/DB16295
    ApprovedInvestigational

    regulatory history outside the United States: China's National Medical Products Administration approved it in December 2020 under the trade name Sishuning, and its Chinese label has since expanded to cover

  5. Drug

    VX-702

    go.drugbank.com/drugs/DB05470
    Investigational

    VX-702 is a small molecule investigational oral anti-cytokine therapy for treatment of inflammatory diseases, specifically rheumatoid arthritis (RA). It acts as a p38 MAP kinase inhibitor. In the future, VX-702 may be investigated for co...

  6. Drug

    Naxitamab

    go.drugbank.com/drugs/DB15965
    ApprovedInvestigational

    [A224474] One stark disadvantage of this therapy is the requirement for concurrent use of granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA).

  7. Drug

    Valdecoxib

    go.drugbank.com/drugs/DB00580
    ApprovedWithdrawn

    Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke.

  8. Drug

    Tetrathiomolybdate

    go.drugbank.com/drugs/DB05088
    Investigational

    Tetrathiomolybdate is an oral, small-molecule, anticopper agent that is highly specific for lowering the levels of free copper in serum. COPREXA has completed pivotal clinical trials for the treatment of neurologic Wilson's disease. It i...

  9. Drug

    CRx-139

    go.drugbank.com/drugs/DB05744
    Experimental

    CRx-139 is an oral synergistic combination drug candidates with novel mechanisms of action targeting multiple biological pathways simultaneously. It is a dissociated steroid designed to enhance the immuno-modulatory activity of a low-dos...

  10. Drug

    Umbilical Cord Blood Hematopoietic Stem Cells

    go.drugbank.com/drugs/DB15723
    Investigational

    Because HUCBC are largely immature, do not express class II HLA antigens, and do not produce as many cytokines and immunoglobulins as adult lymphocytes, transplantation with these cells means low levels